Maintelyte

Magnesium chloride hexahydrate, potassium chloride, sodium chloride, glucose and sodium acetate trihydrate, the active ingredients in Maintelyte, is an electrolyte solution presented as a solution for injection for intravenous use. It helps restore fluid and electrolyte balance in patients experiencing electrolyte depletion, fluid loss, or hypomagnesemia.

GNH USA supplies Maintelyte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Maintelyte is used to replace lost electrolytes and fluids in clinical situations where electrolyte balance is compromised. - Electrolyte depletion: Restores magnesium, potassium, sodium and acetate levels, helping to correct electrolyte imbalances. - Fluid loss: Provides isotonic fluid volume to support intravascular volume and prevent hypovolemia. - Hypomagnesemia: Supplies magnesium chloride to raise serum magnesium concentrations in patients with low magnesium.

Maintelyte may be associated with adverse reactions related to its electrolyte composition and intravenous administration.

Common Side Effects: - Injection site pain or irritation: mild discomfort, redness or swelling at the infusion site. - Mild hyperkalemia: slight, transient increase in serum potassium that usually resolves without intervention. - Nausea or vomiting: occasional gastrointestinal upset occurring during or shortly after the infusion. - Headache: transient headache reported by some patients, often resolving with routine care.

Serious or Rare Side Effects: - Severe hyperkalemia: marked elevation of potassium that can precipitate cardiac arrhythmia and requires immediate treatment. - Severe hypermagnesemia: excessive magnesium levels causing hypotension, respiratory depression, or cardiac conduction abnormalities. - Anaphylactic reaction: rare hypersensitivity presenting with rash, bronchospasm, urticaria, or circulatory collapse.

When using Maintelyte, clinicians should observe specific precautions to ensure patient safety and product integrity. - Assess electrolyte status: verify baseline serum magnesium, potassium and sodium levels before infusion. - Monitor cardiac function: observe ECG for arrhythmias during and after administration. - Adjust infusion rate: tailor speed according to patient volume status and renal function. - Avoid in severe renal impairment: reduced clearance may lead to electrolyte accumulation. - Use aseptic technique: maintain sterility to prevent contamination. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Maintelyte can interact with other agents that affect electrolyte balance or cardiac conduction.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): may cause dangerous hyperkalemia when combined with the potassium in Maintelyte. - Calcium channel blockers (e.g., verapamil, diltiazem): electrolyte shifts can increase risk of bradyarrhythmia. - Magnesium‑containing laxatives or antacids: concurrent use can lead to excessive magnesium accumulation.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate hyperkalemia; serum potassium should be closely monitored. - Loop diuretics (e.g., furosemide): can cause rapid electrolyte changes; infusion rate may need adjustment. - Sodium bicarbonate therapy: adds additional sodium load, potentially affecting fluid balance and acid‑base status.